Najat Khan

CEO and President, Recursion · Person

Mentions

Episodes

Claims

Najat Khan - CEO and President, Recursion. Tracked across 16 mentions in podcasts and expert conversations analyzed by Sonic.

What Najat Khan has said

AI algorithms are now included in the NCCN (National Comprehensive Cancer Network) clinical guidelines for patient stratification.

bullish·Najat Khan

Recursion's FAP drug achieved its median polyp reduction after three months of treatment, whereas other experimental drugs have taken 12 months to achieve approximately half that effect.

bullish·Najat Khan

The reduction in polyp burden from Recursion's FAP drug was sustained for at least three months after patients stopped taking the medication.

bullish·Najat Khan

AI algorithms are now included in the NCCN (National Comprehensive Cancer Network) clinical guidelines for patient stratification.

Expert perspectiveNajat KhanApr 20

Recursion's FAP drug achieved its median polyp reduction after three months of treatment, whereas other experimental drugs have taken 12 months to achieve approximately half that effect.

Expert perspectiveNajat KhanApr 20

The reduction in polyp burden from Recursion's FAP drug was sustained for at least three months after patients stopped taking the medication.

Expert perspectiveNajat KhanApr 20

Recursion's integration with Exscientia expanded its capabilities from novel biology discovery to AI-driven small molecule design.

Expert perspectiveNajat KhanApr 20

Recursion's strategy is to be an end-to-end platform covering biology, chemistry, and clinical development, differentiating it from competitors who focus on point solutions.

Expert perspectiveNajat KhanApr 20

Familial adenomatous polyposis (FAP) affects over 50,000 patients in the United States and European Union.

Expert perspectiveNajat KhanApr 20

There are currently no approved pharmacotherapies for familial adenomatous polyposis (FAP), with surgery being the only standard of care.

Expert perspectiveNajat KhanApr 20

There are currently no approved disease-modifying drugs for Parkinson's disease.

Expert perspectiveNajat KhanApr 20

Recursion synthesizes an average of 330 compounds to identify a final drug candidate, compared to an industry average of 5,000.

Expert perspectiveNajat KhanApr 20

Recursion plans to begin conversations with the FDA this year to design a Phase 3 registrational study for its familial adenomatous polyposis (FAP) drug.

Expert perspectiveNajat KhanApr 20

Recursion has generated a dataset of one trillion iPSC-derived neuronal cells in which every gene in the human genome has been knocked out.

Expert perspectiveNajat KhanApr 20

Patients with familial adenomatous polyposis (FAP) have a 100% risk of developing colorectal cancer if the condition is left untreated.

Expert perspectiveNajat KhanApr 20

Recursion positions itself as the first end-to-end, AI-native platform company for drug discovery and development.

Expert perspectiveNajat KhanApr 20

In clinical trials, Recursion's drug for familial adenomatous polyposis (FAP) demonstrated a 43% median reduction in polyp burden.

Expert perspectiveNajat KhanApr 20

Recursion's drug design process takes an average of 17 months, compared to an industry average of 42 months.

Expert perspectiveNajat KhanApr 20

Recursion's platform identified that an allosteric MEK1/2 inhibitor can reverse the cellular phenotype of APC gene loss-of-function, a novel biological insight.

Expert perspectiveNajat KhanApr 20

Create a free account to see Najat Khan's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail